Apogee Enterprises' chief executive, Ty Silberhorn, is leaving the architectural products and services company. Apogee on Friday said its independent chairman, Donald Nolan, will now serve as ...

Apogee Enterprises, Inc. (Nasdaq: APOG) announced today that Apogee Enterprises’ Independent Chair Donald A. Nolan has been appointed as the Company’s Chief Executive Officer, effective October 31, ...

Apogee Enterprises, Inc.'s (NASDAQ:APOG) earnings announcement last week didn't impress shareholders. While the headline numbers were soft, we believe that investors might be missing some encouraging ...

Apogee Enterprises ((APOG)) has held its Q2 earnings call. Read on for the main highlights of the call. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, ...

Apogee saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Apogee’s stock price’s past reactions to earnings here. According to InvestingPro, Apogee’s Financial Health ...

MINNEAPOLIS, October 09, 2025--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a ...

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...

Apogee Enterprises (NASDAQ:APOG) will release its quarterly earnings report on Thursday, 2025-10-09. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Apogee ...

Architectural products company Apogee (NASDAQ:APOG) will be reporting earnings this Thursday afternoon. Here’s what investors should know. Apogee beat analysts’ revenue expectations by 6.3% last ...

Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its mid-stage trial for APG777, an antibody treatment aimed at moderate-to-severe ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial. The mid-stage study saw 123 adults with ...

Apogee Therapeutics Inc. (NASDAQ:APGE) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday. This substantial increase in stock price follows the release of ...